Solskin/DigitalVision via Getty Images Roivant Sciences Ltd. ( ROIV ) is a late-stage biotechnology company that operates through subsidiaries called Vants. Its current pipeline is centered on immunology and specialty diseases. ROIV also has brepocitinib, a TYK2/JAK1 inhibitor being developed by Priovant for dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris. A...
Solskin/DigitalVision via Getty Images Roivant Sciences Ltd. ( ROIV ) is a late-stage biotechnology company that operates through subsidiaries called Vants. Its current pipeline is centered on immunology and specialty diseases. ROIV also has brepocitinib, a TYK2/JAK1 inhibitor being developed by Priovant for dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris. Aside from that, ROIV’s mosliciguat is an inhaled sGC activator for pulmonary hypertension associated with interstitial lung disease. And ROIV’s Immunovant has other FcRn programs, including IMVT-1402 and batoclimab. Recently, they settled with Moderna ( MRNA ) about their COVID-19 patents, giving ROIV a first payment of $950 million in July 2026 and a potential second payment of $1.3 billion. As such, while my bull case has largely played out, I believe the stock is now well-positioned to deliver consistent shareholder value for investors with a long-term time horizon. A Successful Vant Story Roivant Sciences Ltd. is a biotech company that develops medicines through its specialized subsidiaries, known as Vants. Each Vant focuses on a specific therapeutic area to speed up drug development. ROIV was founded back in 2014 and is based in London, with offices in New York and Basel, Switzerland. I’ve been following ROIV for a while now. And since my latest November 2025 article, the stock has appreciated another 32.2%. In fact, the stock is up around 150.9% from the first time I covered it, so now I feel it’s appropriate to write another update to my bull case. Source: Corporate Presentation. April 2026. Currently, ROIV is focused on immunology and specialty diseases. One of its main drugs is brepocitinib , a TYK2/JAK1 inhibitor developed by Priovant for inflammatory conditions. This asset targets conditions like dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. And an important upcoming brepocitinib milestone is for dermatomyositis, a rare autoimmune disease th...
M.photostock/iStock via Getty Images If you’ve been building a dividend income portfolio like I have, you’re probably familiar with the satisfaction of watching dividend checks arrive month after month. But what if there was a way to amplify that income without significantly increasing your risk? That’s where covered call ETFs come in. And before you assume it’s some complicated options strategy m...
M.photostock/iStock via Getty Images If you’ve been building a dividend income portfolio like I have, you’re probably familiar with the satisfaction of watching dividend checks arrive month after month. But what if there was a way to amplify that income without significantly increasing your risk? That’s where covered call ETFs come in. And before you assume it’s some complicated options strategy meant only for experienced traders - it’s not. It’s actually a natural extension of what dividend investors are already doing. A covered call ETF holds a basket of dividend-paying stocks while simultaneously selling call options on those same holdings. Here’s the simple version: when you own shares, you’re giving someone else the right (but not the obligation) to buy those shares at a set price. In return, you get paid a premium. That premium is extra income on top of your regular dividends. Think of it like this: you own a dividend-paying stock earning you 3% per year. A covered call version of that same fund might earn you 3% from dividends plus 4-8% from call premiums annually. It’s not magic - there’s a trade-off - but it’s a legitimate way to boost returns. I’ve always believed in buy-and-hold discipline. I don’t try to time the market or chase quick gains. I buy quality dividend stocks and hold them for years, collecting paychecks from the companies I own. Covered call ETFs fit perfectly into that philosophy. You’re not day trading or gambling. You’re still holding dividend stocks for the long term - the fund just adds an income stream through call selling. The key insight: covered call funds work best when stock prices are stable or rising slowly. If you own a dividend stock yielding 3% and expect it to appreciate 4-6% annually, selling calls is a smart way to harvest some of that expected upside as immediate income. If the stock price shoots up dramatically, your shares might get called away at the strike price. You miss out on that extra gain. That’s the one caveat ...
(RTTNews) - JinkoSolar Holding Co. (JKS), solar module manufacturer, on Wednesday reported narrower loss for the first quarter from a year earlier despite lower revenue. Further, the company maintained its full- year shipment guidance.
(RTTNews) - JinkoSolar Holding Co. (JKS), solar module manufacturer, on Wednesday reported narrower loss for the first quarter from a year earlier despite lower revenue. Further, the company maintained its full- year shipment guidance.
Kelly Sullivan/Getty Images Entertainment Meta Platforms ( META ) options traders are pricing in a significant post-earnings swing Wednesday, with the company’s May 1 weekly options chain implying a move of roughly $49 per share by Friday’s expiration. With shares trading around $671 a share in late-morning action, the near-the-money 670 straddle shows traders expecting about 7.3% volatility aroun...
Kelly Sullivan/Getty Images Entertainment Meta Platforms ( META ) options traders are pricing in a significant post-earnings swing Wednesday, with the company’s May 1 weekly options chain implying a move of roughly $49 per share by Friday’s expiration. With shares trading around $671 a share in late-morning action, the near-the-money 670 straddle shows traders expecting about 7.3% volatility around the earnings release. Meta ( META ) is set to report first-quarter results after the market close, with its earnings call set for 5:30 p.m. ET. Positioning appears especially heavy on the upside. The 700 call carried 10,953 contracts of open interest, while the 710 call held 12,564 contracts, the largest visible concentration in the chain near the post-earnings upside zone. The 750 call also showed 4,346 contracts of open interest. The put side was active but more dispersed, with the 650 put carrying 4,256 contracts of open interest and the 600 put holding 4,430 contracts, indicating meaningful downside protection well below the stock’s trading level. With the 670 straddle priced near $49, Meta ( META ) needs to move beyond roughly $621 or $719 by Friday for buyers of near-the-money volatility to profit. Anything inside that range would leave options traders unrewarded despite a notable move. Investors will be laser-focused on the company's capital expenditure outlook, particularly in AI, with the company planning $60B-$65B in infrastructure investments this year. Meta ( META ) closed out last year beating Wall Street expectations for revenues and profitability and setting strong expectations for first-quarter revenues but raised the bar on expected infrastructure spending. More on Meta Meta Q1: AI Ad Thesis Getting Stronger Meta's Stock May Plunge Following Results Meta Vs. Google: In The Age Of AI, The Ad Crown Is Up For Grabs European Commission finds Meta fails to keep minors off platform Meta after the bell: Prediction markets flag Threads, AI, and cloud momentum
Kelly Sullivan/Getty Images Entertainment Meta Platforms ( META ) options traders are pricing in a significant post-earnings swing Wednesday, with the company’s May 1 weekly options chain implying a move of roughly $49 per share by Friday’s expiration. With shares trading around $671 a share in late-morning action, the near-the-money 670 straddle shows traders expecting about 7.3% volatility aroun...
Kelly Sullivan/Getty Images Entertainment Meta Platforms ( META ) options traders are pricing in a significant post-earnings swing Wednesday, with the company’s May 1 weekly options chain implying a move of roughly $49 per share by Friday’s expiration. With shares trading around $671 a share in late-morning action, the near-the-money 670 straddle shows traders expecting about 7.3% volatility around the earnings release. Meta ( META ) is set to report first-quarter results after the market close, with its earnings call set for 5:30 p.m. ET. Positioning appears especially heavy on the upside. The 700 call carried 10,953 contracts of open interest, while the 710 call held 12,564 contracts, the largest visible concentration in the chain near the post-earnings upside zone. The 750 call also showed 4,346 contracts of open interest. The put side was active but more dispersed, with the 650 put carrying 4,256 contracts of open interest and the 600 put holding 4,430 contracts, indicating meaningful downside protection well below the stock’s trading level. With the 670 straddle priced near $49, Meta ( META ) needs to move beyond roughly $621 or $719 by Friday for buyers of near-the-money volatility to profit. Anything inside that range would leave options traders unrewarded despite a notable move. Investors will be laser-focused on the company's capital expenditure outlook, particularly in AI, with the company planning $60B-$65B in infrastructure investments this year. Meta ( META ) closed out last year beating Wall Street expectations for revenues and profitability and setting strong expectations for first-quarter revenues but raised the bar on expected infrastructure spending. More on Meta Meta Q1: AI Ad Thesis Getting Stronger Meta's Stock May Plunge Following Results Meta Vs. Google: In The Age Of AI, The Ad Crown Is Up For Grabs European Commission finds Meta fails to keep minors off platform Meta after the bell: Prediction markets flag Threads, AI, and cloud momentum
Torsten Asmus U.S. Treasury yields climbed to one-month highs on Wednesday as a broad bond selloff swept across the market, reflecting renewed inflation concerns and shifting rate expectations. The move was led by the front end of the curve, with the U.S. 2 Year Treasury yield ( US2Y ) rising five basis points to 3.90%, marking its highest level since March 27. Longer-dated yields followed suit. T...
Torsten Asmus U.S. Treasury yields climbed to one-month highs on Wednesday as a broad bond selloff swept across the market, reflecting renewed inflation concerns and shifting rate expectations. The move was led by the front end of the curve, with the U.S. 2 Year Treasury yield ( US2Y ) rising five basis points to 3.90%, marking its highest level since March 27. Longer-dated yields followed suit. The benchmark U.S. 10 Year Treasury yield ( US10Y ) advanced four basis points to 4.39%, reaching its highest point since March 30. Meanwhile, the U.S. 30 Year Treasury yield ( US30Y ) gained a similar margin to 4.98%, also its strongest level since late March. The US30Y is now also within striking distance of the 5% threshold—a level not seen since early September. The upward pressure on yields comes as investors react to a sharp rise in energy prices, a key driver of inflation expectations. Crude oil ( CL1:COM ) surged more than 5%, pushing prices back above the $100-per-barrel mark and reigniting concerns about persistent price pressures. The combination of rising yields and higher oil prices underscores growing unease in fixed-income markets, as traders reassess the outlook for monetary policy and the potential for rates to remain elevated for longer. Fixed Income ETFs: ( TLT ), ( TLH ), ( IEF ), ( IEI ), ( SHY ), ( SGOV ), ( SCHO ), ( BIL ), ( AGG ), ( BND ), ( VCIT ), ( MUB ), ( MBB ), ( JNK ), ( LQD ), ( HYG ), ( VTIP ), ( TIP ), ( SCHP ), ( STIP ), ( TIPX ), ( SPIP ), ( WIP ), ( GTIP ), ( LQDI ), and ( RINF ). More on markets Oil tops $100 again and the United States Oil Fund LP ETF hit its highest level since 2015 Ray Dalio says a wealth tax may spark a bubble pop Big Tech earnings test AI spending as constraints begin to surface, Citi says Fed meeting ahead: Prediction markets highlight what Powell may signal Only 11 mega-caps stand out in SA Quant Ratings as markets hover near highs
In recent trading, shares of Genesco Inc. (Symbol: GCO) have crossed above the average analyst 12-month target price of $36.00, changing hands for $36.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuatio
In recent trading, shares of Genesco Inc. (Symbol: GCO) have crossed above the average analyst 12-month target price of $36.00, changing hands for $36.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuatio
In recent trading, shares of Alerus Financial Corp (Symbol: ALRS) have crossed above the average analyst 12-month target price of $26.00, changing hands for $26.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade o
In recent trading, shares of Alerus Financial Corp (Symbol: ALRS) have crossed above the average analyst 12-month target price of $26.00, changing hands for $26.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade o